Cell and gene therapies (CGTs) are poised for significant growth, with the global CGT contract development and manufacturing organization (CDMO) market projected to expand from $8.07 billion in 2025 to approximately $74.03 billion by 2034, reflecting a compound annual growth rate (CAGR) of 27.92%. This surge is driven by increasing demand for specialized expertise and regulatory knowledge in the development and manufacturing of these advanced therapies.
Despite this optimistic outlook, the CGT sector faces substantial challenges, particularly in manufacturing and drug delivery. High treatment costs, exemplified by Orchard Therapeutics’ Lenmeldy priced at $4.25 million, complicate market access and reimbursement efforts. As investment in CGT developers has declined, the sector’s growth trajectory remains uncertain, with funding levels significantly lower than the peak seen in 2021.
Industry experts highlight the need for CDMOs to possess a unique blend of technical capabilities and commercial experience to navigate the complexities of CGT production. As the market evolves, successful partnerships will hinge on transparent communication and shared goals, underscoring the critical role of innovation in overcoming current hurdles and ensuring future growth.
Get started today with Solo access →
